International clinical trials of the Sputnik Light single-dose vaccine have begun in the Russian capital, Moscow Mayor Sergei Sobyanin wrote in a blog post on Thursday.
“Today, we are launching international clinical trials of the Sputnik Light vaccine. The new vaccine developed by the Gamaleya Institute is meant to eliminate the main disadvantage of the classic Sputnik V – the presence of two components administered to patients at an interval of several weeks. To get vaccinated with Sputnik Light, a person will need only one visit to an outpatient clinic. Immunity will begin to develop a week later, and it will reach the maximum level four weeks after the vaccination,” the mayor wrote.
According to Sobyanin, a total of 6,000 people will take part in the clinical trials of the Sputnik Light vaccine, 3,000 of them will be from Russia and another 3,000 from the UAE.
Sputnik Light has already passed the first phases of clinical trials. Everyone who received it developed immunity to COVID-19,” he added.
The mayor noted that the Russian part of the trials would take place at ten outpatient clinics in Moscow. Any adult citizen who has not been vaccinated with Sputnik V and has no other contraindications can take part in them.